Compounds > 2-phenoxyphenol
Page last updated: 2024-11-06

2-phenoxyphenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-Phenoxyphenol, also known as o-phenoxyphenol, is an organic compound with the formula C12H10O2. It is a white solid that is soluble in organic solvents. 2-phenoxyphenol is a fungicide that is used to protect plants from fungal diseases. It is also used as an intermediate in the synthesis of other chemicals. The compound is synthesized through a variety of methods, including the reaction of phenol with bromobenzene in the presence of a base. 2-phenoxyphenol is a potent inhibitor of the enzyme cytochrome P450, which is involved in the metabolism of many drugs and toxins. This compound has been studied for its potential applications in agriculture and medicine. Research has shown that it exhibits fungicidal and bactericidal properties. It is also being investigated for its potential to treat cancer and other diseases.'

Cross-References

ID SourceID
PubMed CID75491
CHEMBL ID148515
CHEBI ID39261
SCHEMBL ID260447

Synonyms (38)

Synonym
2-phenoxy-phenol
2-phenoxyphenol
phenol, 2-phenoxy-
BIONET2_001265
o-phenoxyphenol
2417-10-9
2-hydroxydiphenyl ether
CHEBI:39261 ,
HMS1367J11
CHEMBL148515
AKOS005084057
2-phenoxylphenol
bdbm36537
pt51
unii-kvi8n9886n
kvi8n9886n ,
FT-0648308
AM20030427
SCHEMBL260447
1W-0639
phenoxyphenol
54774-79-7
mfcd00093034
2-phenoxybenzenol
P-2980
CS-W019370
2-hydroxyphenyl phenyl ether
phenoxyphenol, o-
phenol, o-phenoxy-
2-phenoxyphenol #
DTXSID00178879
phenol,2-phenoxy-
phenol, phenoxy-
A1-05146
EN300-1868882
Q27119795
A918766
CAA41710
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenoxyphenol
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Enoyl-[acyl-carrier-protein] reductase [NADPH] FabIStaphylococcus aureus subsp. aureus MRSA252Ki0.01890.00000.00950.0189AID1799923
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty acid-binding protein, intestinalHomo sapiens (human)K10.50000.50000.50000.5000AID71603
Fatty acid-binding protein, intestinalHomo sapiens (human)K20.40000.40000.40000.4000AID71604
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
fatty acid metabolic processFatty acid-binding protein, intestinalHomo sapiens (human)
long-chain fatty acid transportFatty acid-binding protein, intestinalHomo sapiens (human)
intestinal lipid absorptionFatty acid-binding protein, intestinalHomo sapiens (human)
fatty acid transportFatty acid-binding protein, intestinalHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
long-chain fatty acid transmembrane transporter activityFatty acid-binding protein, intestinalHomo sapiens (human)
fatty acid bindingFatty acid-binding protein, intestinalHomo sapiens (human)
protein bindingFatty acid-binding protein, intestinalHomo sapiens (human)
long-chain fatty acid bindingFatty acid-binding protein, intestinalHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytosolFatty acid-binding protein, intestinalHomo sapiens (human)
microvillusFatty acid-binding protein, intestinalHomo sapiens (human)
apical cortexFatty acid-binding protein, intestinalHomo sapiens (human)
cytosolFatty acid-binding protein, intestinalHomo sapiens (human)
nucleusFatty acid-binding protein, intestinalHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1799923Thermal Shift Assay from Article 10.1021/bi400413c: \\Rational Optimization of Drug-Target Residence Time: Insights from Inhibitor Binding to the Staphylococcus aureus FabI Enzyme-Product Complex.\\2013Biochemistry, Jun-18, Volume: 52, Issue:24
Rational optimization of drug-target residence time: insights from inhibitor binding to the Staphylococcus aureus FabI enzyme-product complex.
AID1799428Enzyme Inhibition Assay from Article 10.1021/cb800306y: \\Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity.\\2009ACS chemical biology, Mar-20, Volume: 4, Issue:3
Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity.
AID71605Ionisation constant for the compound2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.
AID1296789Antimicrobial activity against methicillin-resistant Staphylococcus aureus OM481 clinical isolate after 18 to 20 hrs by liquid microdilution method2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Minimum structural requirements for cell membrane leakage-mediated anti-MRSA activity of macrocyclic bis(bibenzyl)s.
AID1296788Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315 after 18 to 20 hrs by liquid microdilution method2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Minimum structural requirements for cell membrane leakage-mediated anti-MRSA activity of macrocyclic bis(bibenzyl)s.
AID71603In vitro inhibitory activity against wild-type intestinal Fatty acid-binding protein (FabI) of Escherichia coli expressed as K12004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.
AID1059056Bacteriostatic activity against methicillin-resistant Staphylococcus aureus at 4 times MIC by cell survival assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives.
AID717875Antibacterial activity against methicillin-resistant Staphylococcus aureus OM584 by two-fold liquid microdilution method2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Riccardin C derivatives as anti-MRSA agents: structure-activity relationship of a series of hydroxylated bis(bibenzyl)s.
AID1059061Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate OM584 by liquid microdilution method2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives.
AID1296790Antimicrobial activity against 2-phenoxyphenol/methicillin-resistant Staphylococcus aureus after 18 to 20 hrs by liquid microdilution method2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Minimum structural requirements for cell membrane leakage-mediated anti-MRSA activity of macrocyclic bis(bibenzyl)s.
AID717874Antibacterial activity against methicillin-resistant Staphylococcus aureus OM481 by two-fold liquid microdilution method2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Riccardin C derivatives as anti-MRSA agents: structure-activity relationship of a series of hydroxylated bis(bibenzyl)s.
AID1059057Bactericidal activity against methicillin-resistant Staphylococcus aureus at 4 times MIC by cell survival assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives.
AID1059060Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate N315 by liquid microdilution method2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives.
AID1059062Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate OM481 by liquid microdilution method2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives.
AID69489Minimum inhibitory concentration against Escherichia coli was determined2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.
AID71604In vitro inhibitory activity against wild-type intestinal Fatty acid-binding protein (FabI) of Escherichia coli expressed as K22004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.97 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
triclosan
[no description available]		2.7430aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols		antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic
2,2'-bisphenol f
2,2'-bisphenol F: contact allergen; structure given in first source		2.0210diarylmethane
lunularin
lunularin: first source misnames compound; structure in first source		2.520stilbenoid
linezolid
[no description available]		2.4820acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
riccardin c
riccardin C: isolated from liverworts; functions as a liver X receptor (LXR)alpha agonist and an LXRbeta antagonist; structure in first source		2.7830
riccardin d
riccardin D: antifungal agent isolated from Dumortiera hirsute; structure in first source		2.0810
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0510
Francisella tularensis Infection
[description not available]		02.0510
Tularemia
A plague-like disease of rodents, transmissible to man. It is caused by FRANCISELLA TULARENSIS and is characterized by fever, chills, headache, backache, and weakness.		02.0510